Several of the humanized IGF-1R antibodies and small receptor tyrosine kinase (RTK) inhibitors have been subjected to investigations in MM in in vitro studies, preclinical mouse models of MM, and in clinical trials (51,67,68). The gene discussed is IGF1R; the disease is Miyoshi myopathy.